Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Back to News index

Reaction to EMA decision

Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA), said: “We congratulate Amsterdam on being selected as the new location for the European Medicines Agency. But the location of the EMA is secondary to the necessity to maintain the efficient regulatory system already in place which benefits patients and the industry alike. It is now critical that the Brexit negotiations deliver a level of certainty as soon as possible so the whole medicines supply chain can plan ahead and ensure security of supply is not impacted. We continue to call for the UK to remain part of the European medicines licensing environment so that patients continue to receive the right medicine, at the right time, in the right place without further burden or obstruction being added.”